726 related articles for article (PubMed ID: 19417025)
21. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.
Hui EP; Lui VW; Wong CS; Ma BB; Lau CP; Cheung CS; Ho K; Cheng SH; Ng MH; Chan AT
Invest New Drugs; 2011 Dec; 29(6):1123-31. PubMed ID: 20467883
[TBL] [Abstract][Full Text] [Related]
22. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.
Shojaei F; Lee JH; Simmons BH; Wong A; Esparza CO; Plumlee PA; Feng J; Stewart AE; Hu-Lowe DD; Christensen JG
Cancer Res; 2010 Dec; 70(24):10090-100. PubMed ID: 20952508
[TBL] [Abstract][Full Text] [Related]
23. Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts.
Gaustad JV; Simonsen TG; Andersen LMK; Rofstad EK
BMC Cancer; 2017 Jun; 17(1):411. PubMed ID: 28606060
[TBL] [Abstract][Full Text] [Related]
24. Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals.
Suddek GM
Cancer Chemother Pharmacol; 2011 May; 67(5):1035-44. PubMed ID: 20652569
[TBL] [Abstract][Full Text] [Related]
25. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
[TBL] [Abstract][Full Text] [Related]
26. Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction.
Kleibeuker EA; Ten Hooven MA; Castricum KC; Honeywell R; Griffioen AW; Verheul HM; Slotman BJ; Thijssen VL
Cancer Med; 2015 Jul; 4(7):1003-15. PubMed ID: 25828633
[TBL] [Abstract][Full Text] [Related]
27. ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.
Juliachs M; Castillo-Ávila W; Vidal A; Piulats JM; Garcia Del Muro X; Condom E; Hernández-Losa J; Teixidó C; Pandiella A; Graupera M; Casanovas O; Germà JR; Villanueva A; Viñals F
Int J Cancer; 2013 Jul; 133(1):235-46. PubMed ID: 23292912
[TBL] [Abstract][Full Text] [Related]
28. Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.
Hillman GG; Singh-Gupta V; Zhang H; Al-Bashir AK; Katkuri Y; Li M; Yunker CK; Patel AD; Abrams J; Haacke EM
Neoplasia; 2009 Sep; 11(9):910-20. PubMed ID: 19724685
[TBL] [Abstract][Full Text] [Related]
29. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.
Subbiah V; Meric-Bernstam F; Mills GB; Shaw KR; Bailey AM; Rao P; Ward JF; Pagliaro LC
J Hematol Oncol; 2014 Aug; 7():52. PubMed ID: 25085632
[TBL] [Abstract][Full Text] [Related]
30. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
[TBL] [Abstract][Full Text] [Related]
31. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
32. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.
Zhou Q; Guo P; Gallo JM
Clin Cancer Res; 2008 Mar; 14(5):1540-9. PubMed ID: 18316579
[TBL] [Abstract][Full Text] [Related]
33. Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
Nitzsche B; Gloesenkamp C; Schrader M; Hoffmann B; Zengerling F; Balabanov S; Honecker F; Höpfner M
Br J Cancer; 2012 Nov; 107(11):1853-63. PubMed ID: 23169338
[TBL] [Abstract][Full Text] [Related]
34. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.
Cassinelli G; Lanzi C; Tortoreto M; Cominetti D; Petrangolini G; Favini E; Zaffaroni N; Pisano C; Penco S; Vlodavsky I; Zunino F
Biochem Pharmacol; 2013 May; 85(10):1424-32. PubMed ID: 23466421
[TBL] [Abstract][Full Text] [Related]
35. Role of N-cadherin in proliferation, migration, and invasion of germ cell tumours.
Bremmer F; Schallenberg S; Jarry H; Küffer S; Kaulfuss S; Burfeind P; Strauß A; Thelen P; Radzun HJ; Ströbel P; Honecker F; Behnes CL
Oncotarget; 2015 Oct; 6(32):33426-37. PubMed ID: 26451610
[TBL] [Abstract][Full Text] [Related]
36. The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors.
Jing C; Ning J; Yuanjie N
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2137-43. PubMed ID: 22868821
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapeutic sensitivity of testicular germ cell tumors under hypoxic conditions is negatively regulated by SENP1-controlled sumoylation of OCT4.
Wu YC; Ling TY; Lu SH; Kuo HC; Ho HN; Yeh SD; Shen CN; Huang YH
Cancer Res; 2012 Oct; 72(19):4963-73. PubMed ID: 23002208
[TBL] [Abstract][Full Text] [Related]
38. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M
BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898
[TBL] [Abstract][Full Text] [Related]
39. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
Bergers G; Song S; Meyer-Morse N; Bergsland E; Hanahan D
J Clin Invest; 2003 May; 111(9):1287-95. PubMed ID: 12727920
[TBL] [Abstract][Full Text] [Related]
40. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]